Buy These 3 Stocks to Cash In on the Genomics Revolution
If human history is any indication, scientific progress is one of the few trends investors can rely on to drive long-term growth. That's especially true for progress in the field of genomics, where increasingly sophisticated gene editing and gene analysis technologies create new opportunities in science and medicine at an increasingly fast pace.
Genomics companies need to spend significant portions of their revenue on research and development (R&D), which can put a drag on their earnings. But that spending is exactly what advances the field and drives its aggressive growth. Right now, genomics is an industry worth around $19 billion in terms of revenue. According to a 2019 report by Fortune Business Insights, the genomics market will grow at a compound annual rate of more than 19% through 2027, potentially reaching a value of $82.6 billion. Investors looking to capture some of that action in their own portfolios will need to pick the right genomics stocks.
Image source: Getty Images.
Source Fool.com
